PMID- 19893314
OWN - NLM
STAT- MEDLINE
DCOM- 20100301
LR  - 20181201
IS  - 1421-9824 (Electronic)
IS  - 1420-8008 (Linking)
VI  - 28
IP  - 5
DP  - 2009
TI  - Safety and tolerability of donepezil, rivastigmine and galantamine for patients 
      with Alzheimer's disease: systematic review of the 'real-world' evidence.
PG  - 389-403
LID - 10.1159/000255578 [doi]
AB  - BACKGROUND/AIMS: The purpose of this systematic review was to compare the safety 
      and tolerability of the cholinesterase inhibitors (ChEIs) donepezil, rivastigmine 
      and galantamine for treating mild to moderate Alzheimer's disease (AD) patients 
      in routine clinical practice. METHODS: Electronic databases (Cochrane Library, 
      Medline, EMBASE; accessed October 2008) and manual bibliographic searches were 
      conducted to identify head-to-head non-randomised studies examining ChEIs for the 
      treatment of AD. Data were extracted by 2 independent reviewers. RESULTS: Twelve 
      head-to-head studies comparing ChEIs met the pre-specified inclusion criteria; 6 
      retrospective analyses and 6 prospective cohort studies. Donepezil was the most 
      widely studied treatment and galantamine the least widely prescribed therapy. 
      Fewer donepezil-treated subjects withdrew due to adverse events (AEs) compared 
      with rivastigmine and galantamine-treated subjects. The incidence of 
      gastrointestinal (GI) AEs was lower following treatment with donepezil compared 
      with rivastigmine and galantamine. Non-GI (CNS and cardiovascular) AEs occurred 
      at a low frequency, and had a similar incidence in subjects treated with the 
      different ChEIs. CONCLUSIONS: Subjects with mild to moderate AD treated in 
      routine clinical practice with donepezil were more adherent to pharmacotherapy, 
      and had a lower risk of GI AEs compared with rivastigmine or galantamine. This 
      finding accords with results reported in the randomised clinical trial 
      literature.
CI  - Copyright 2009 S. Karger AG, Basel.
FAU - Lockhart, I A
AU  - Lockhart IA
AD  - Pfizer Ltd., Walton-On-The-Hill, Surrey KT20 7NS, UK. Ian.Lockhart @ pfizer.com
FAU - Mitchell, S A
AU  - Mitchell SA
FAU - Kelly, S
AU  - Kelly S
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20091106
PL  - Switzerland
TA  - Dement Geriatr Cogn Disord
JT  - Dementia and geriatric cognitive disorders
JID - 9705200
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Indans)
RN  - 0 (Phenylcarbamates)
RN  - 0 (Piperidines)
RN  - 0D3Q044KCA (Galantamine)
RN  - 8SSC91326P (Donepezil)
RN  - PKI06M3IW0 (Rivastigmine)
SB  - IM
MH  - Aged
MH  - Alzheimer Disease/*drug therapy
MH  - Cholinesterase Inhibitors/*administration & dosage/adverse effects
MH  - Donepezil
MH  - Evidence-Based Medicine
MH  - Galantamine/*administration & dosage/adverse effects
MH  - Humans
MH  - Indans/*administration & dosage/adverse effects
MH  - Phenylcarbamates/*administration & dosage/adverse effects
MH  - Piperidines/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Rivastigmine
RF  - 51
EDAT- 2009/11/07 06:00
MHDA- 2010/03/02 06:00
CRDT- 2009/11/07 06:00
PHST- 2009/08/12 00:00 [accepted]
PHST- 2009/11/07 06:00 [entrez]
PHST- 2009/11/07 06:00 [pubmed]
PHST- 2010/03/02 06:00 [medline]
AID - 000255578 [pii]
AID - 10.1159/000255578 [doi]
PST - ppublish
SO  - Dement Geriatr Cogn Disord. 2009;28(5):389-403. doi: 10.1159/000255578. Epub 2009 
      Nov 6.